financetom
Business
financetom
/
Business
/
Exclusive | ArcelorMittal joins the race to buy Srei twins
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive | ArcelorMittal joins the race to buy Srei twins
Sep 28, 2022 2:12 PM

The race for two debt-ridden Srei Group companies has intensified with the world's largest steel company, Arcelor Mittal Nippon Steel Ltd, showing interest in acquiring the companies.

Share Market Live

NSE

The steelmaker has submitted an expression of interest (EOI) to acquire Srei Infrastructure Finance Ltd (SIFL) and Srei Equipment Finance Ltd (SEFL), which are undergoing a resolution process under the Insolvency and Bankruptcy Code.

Varde Partners and Arena Investors LP have jointly submitted a bid, while another bid is from the investors’ consortium, Shon Randhawa and Rajesh Viren Shah.

Also Read: Daikin Industries expects doubling AC sales in India by 2025

Varde-Arena’s joint bid for Srei Infrastructure Finance and Srei Equipment Finance is more serious as they have paid around Rs 150 crore as the earnest deposit money, while the Shon Randhawa consortium has put conditions on the EMD. They suggested the inclusion of two clauses in the terms of the resolution plan.

The Srei Group under the RBI-appointed administrator Rajneesh Sharma, since last October, has been able to recover about Rs 2,100 crore. The money is lying on the balance sheets.

The RBI-appointed administrator has admitted claims worth Rs 32,749 crore from the company's creditors. So far, transaction auditor BDO India has classified multiple transactions, totalling about Rs 5,000 crore, as fraudulent.

Also Read: Indus Towers warns Vodafone Idea of service closure over non-payment of dues

There were originally 14 suitors who had submitted expressions of interest to acquire Srei group companies under the Insolvency and Bankruptcy Code (IBC) in March.

The Reserve Bank of India had in early October last year superseded the boards of SIFL and its wholly-owned subsidiary SEFL.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Take-Two Interactive Shares Are Trading Higher Monday: What's Going On?
Take-Two Interactive Shares Are Trading Higher Monday: What's Going On?
Sep 29, 2025
Take-Two Interactive Software, Inc. ( TTWO ) shares are trading higher Monday in sympathy with Electronic Arts, Inc. ( EA ) , which announced it will be acquired for $55 billion. Investors often view large acquisitions in the video game industry as a sign of broader strength in the sector, which can lift peer companies like Take-Two. The premium paid...
InFocus Eyecare Expands in Fayetteville, Tennessee with Acquisition of Lincoln County Vision Center
InFocus Eyecare Expands in Fayetteville, Tennessee with Acquisition of Lincoln County Vision Center
Sep 29, 2025
FAYETTEVILLE, Tenn., Sept. 29, 2025 /PRNewswire/ -- InFocus Eyecare, a growing network of more than 25 full-scope optometry practices, is proud to announce its continued expansion in Tennessee with the acquisition of Lincoln County Vision Center, led by Dr. Bill Womble, O.D. As part of this transition, Dr. Daniel DeJarnatt, a respected optometrist who has served the Fayetteville community for many years, has announced...
Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End
Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End
Sep 29, 2025
02:33 PM EDT, 09/29/2025 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Monday it expects to resubmit its biologics license application for ONS-5010, an investigational treatment for wet macular degeneration, after completing a Type A meeting with the US Food and Drug Administration. After reviewing the agency's feedback and meeting minutes, the company said it expects to resubmit the...
MoonLake's Immunotherapeutics Stock Plummets After Phase 3 Data Readouts
MoonLake's Immunotherapeutics Stock Plummets After Phase 3 Data Readouts
Sep 29, 2025
MoonLake Immunotherapeutics ( MLTX )‘ stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials. The trials used HiSCR75—a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels—as the primary endpoint. Key secondary endpoints included HiSCR50 response rates and improvements in Dermatology Quality...
Copyright 2023-2026 - www.financetom.com All Rights Reserved